Please login to the form below

Not currently logged in
Email:
Password:

Amicus Therapeutics launches Fabry treatment Galafold in Italy

Follows publication of Ministry of Health's reimbursement guidelines

Amicus TherapeuticsUS biotech Amicus Therapeutics has launched its new Fabry disease treatment Galafold (migalastat) in Italy after winning reimbursement coverage.

Final reimbursement guidelines from the Ministry of Health back Galafold for long-term treatment of adults and adolescents aged 16 years and older with a confirmed diagnosis of Fabry disease (alpha-galactosidase A deficiency) and who have an amenable mutation.

John Crowley, Amicus chairman and CEO, said: "The commercial launch of Galafold in Italy is a significant milestone for the Fabry community.

“We believe that our successful pricing and reimbursement in Italy is a testament to the significant value of our oral precision medicine, and reflects our growing momentum with the country-by-country processes to launch Galafold throughout the EU.”

Galafold is the first orally administered alternative to the current crop of injectable enzyme replacement therapies (ERT) for Fabry disease, such as Sanofi's Fabrazyme (agalsidase beta).

Amicus’ therapy is a first-in-class chaperone therapy and works by stabilising the body's own dysfunctional enzyme.

Galafold received NICE backing for England and Wales last month and has been recommended as a treatment option in the US, on condition that Amicus provide it at a discounted rate.

Article by
Dominic Tyer

14th March 2017

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
W2O Group

W2O Group is an integrated marketing agency with expertise in brand and digital strategy, creative development and communications services. We...

Latest intelligence

Virtual Engagement At Porterhouse: Reflections on the past few months
A look at how the pitfalls of virtual engagement can be avoided and the key advantages of virtual client and KOL engagement strategies in a now predominantly digital world....
July 2020: diversity and inclusion in clinical trials round-up
COVID-19 has continued to bring diversity and health inequality to the forefront of people’s attention. Our latest round-up covers the July news around these issues, and brings you the latest...
Medical Device Clinical Trials 2020
In July 2020, we attended and exhibited at the Medical Device Clinical Trials 2020 Virtual Experience. We really enjoyed the day and it was great to hear from like-minded people,...

Infographics